Treats major depressive disorder (MDD). ANDA 204852, held by Aurobindo Pharma. Trazodone Hydrochloride.
As of Nov 16, 2026, ANDA 204852 (Trazodone Hydrochloride), held by Aurobindo Pharma, was first approved by FDA on Feb 5, 2020, with 1 approved supplement and 0 published complete response letters.
Trazodone Hydrochloride Tablets are indicated for the treatment of major depressive disorder (MDD) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 5, 2020 | Original application | Approved | None posted |
| Trazodone Hydrochloride50MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride100MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride150MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride300MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Jun 24, 2025 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters